[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:prostate-carcinoma":3},{"name":4,"total":5,"recruiting":6,"trials":7,"biomarkers":313,"states":398},"Prostate Carcinoma",735,621,[8,16,22,28,34,41,48,54,60,66,72,78,84,90,96,102,108,114,121,127,133,139,145,150,157,163,169,175,181,187,193,199,205,210,216,222,228,234,240,246,252,258,264,270,276,282,289,295,301,307],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06096870","Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy",[12],"Phase 2","RECRUITING","2026-08-26T02:18:21.216897Z","2026-07-24T01:27:14.930066Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT05011383","High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers",[12],"2026-08-26T02:17:47.813245Z","2026-07-24T01:27:14.925238Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06549465","Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)",[12],"2026-08-26T02:16:41.943926Z","2026-07-24T01:27:14.871772Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":32,"content_modified":33},"NCT06378866","Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial",[12],"2026-08-26T02:16:16.995720Z","2026-07-24T01:27:14.871562Z",{"nct_id":35,"title":36,"phases":37,"status":13,"updated_at":39,"content_modified":40},"NCT06136650","A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)",[38],"Phase 3","2026-08-26T02:17:46.653867Z","2026-07-24T01:27:14.871016Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT05413850","Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection",[45],"Phase 1\u002FPhase 2","2026-08-26T02:17:18.747857Z","2026-07-05T05:32:16.802272Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT05168618","Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer",[12],"2026-08-26T02:17:17.791881Z","2026-07-05T05:32:16.800551Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT05422911","Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.",[12],"2026-08-26T02:19:26.493949Z","2026-07-05T05:32:16.800140Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":64,"content_modified":65},"NCT00969111","Postoperative or Salvage Radiotherapy (RT) for Node Negative Prostate Cancer Following Radical Prostatectomy",[],"2026-08-26T02:17:24.721169Z","2026-07-05T05:32:16.768440Z",{"nct_id":67,"title":68,"phases":69,"status":13,"updated_at":70,"content_modified":71},"NCT06568562","XL092 in Patients With Metastatic Castration-Resistant Prostate Cancer",[12],"2026-08-26T02:18:06.247899Z","2026-07-05T05:32:16.762944Z",{"nct_id":73,"title":74,"phases":75,"status":13,"updated_at":76,"content_modified":77},"NCT06592924","Docetaxel to Androgen Receptor Pathway Inhibitors in Patients With Metastatic Castration Sensitive Prostate Cancer and Suboptimal PSA Response",[38],"2026-08-26T02:16:51.982021Z","2026-07-05T05:32:16.762185Z",{"nct_id":79,"title":80,"phases":81,"status":13,"updated_at":82,"content_modified":83},"NCT06533644","A Study of SYNC-T Therapy SV-102 in Participants With Metastatic Castration-Resistant Prostate Cancer",[12],"2026-08-26T02:16:29.226604Z","2026-07-05T05:32:16.760477Z",{"nct_id":85,"title":86,"phases":87,"status":13,"updated_at":88,"content_modified":89},"NCT06520345","The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)",[38],"2026-08-26T02:16:08.402952Z","2026-07-05T05:32:16.759187Z",{"nct_id":91,"title":92,"phases":93,"status":13,"updated_at":94,"content_modified":95},"NCT06392295","PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer",[12],"2026-08-26T02:15:04.877798Z","2026-07-05T05:32:16.751105Z",{"nct_id":97,"title":98,"phases":99,"status":13,"updated_at":100,"content_modified":101},"NCT06236139","Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer",[45],"2026-08-26T02:15:45.413021Z","2026-07-05T05:32:16.748678Z",{"nct_id":103,"title":104,"phases":105,"status":13,"updated_at":106,"content_modified":107},"NCT06274047","PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.",[38],"2026-08-26T02:19:25.538428Z","2026-07-05T05:32:16.748120Z",{"nct_id":109,"title":110,"phases":111,"status":13,"updated_at":112,"content_modified":113},"NCT06111781","The SUGAR Study; SBRT and Relugolix) for Prostate Cancer",[12],"2026-08-26T02:15:52.238965Z","2026-07-05T05:32:16.747956Z",{"nct_id":115,"title":116,"phases":117,"status":13,"updated_at":119,"content_modified":120},"NCT06095089","A Study of JNJ-87189401 Combined With JNJ-78278343 for Advanced Prostate Cancer",[118],"Phase 1","2026-08-26T02:17:48.768272Z","2026-07-05T05:32:16.743269Z",{"nct_id":122,"title":123,"phases":124,"status":13,"updated_at":125,"content_modified":126},"NCT07140900","Study Evaluating the Safety, Tolerability, and Efficacy of Xaluritamig in Combination With Androgen Receptor Pathway Inhibitors in Participants With Metastatic Hormone-sensitive Prostate Cancer",[118],"2026-08-26T02:18:22.309547Z","2026-07-05T05:32:16.736125Z",{"nct_id":128,"title":129,"phases":130,"status":13,"updated_at":131,"content_modified":132},"NCT07027124","Neoadjuvant ADT + Darolutamide With Pembrolizumab, Followed by Adjuvant Pembrolizumab in Molecularly Stratified High-Risk Prostate Cancer",[12],"2026-08-26T02:17:56.243868Z","2026-07-05T05:32:16.731293Z",{"nct_id":134,"title":135,"phases":136,"status":13,"updated_at":137,"content_modified":138},"NCT06879041","A Phase I Study of [225Ac]-AZD2284 in Patients With Metastatic Castration-Resistant Prostate Cancer",[118],"2026-08-26T02:16:55.892527Z","2026-07-05T05:32:16.706910Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":143,"content_modified":144},"NCT06826924","7-Days Water-Only Fasting or Ketone Supplementation Trial in Prostate Cancer",[],"2026-08-26T02:15:03.757872Z","2026-07-05T05:32:16.696882Z",{"nct_id":146,"title":147,"phases":148,"status":13,"updated_at":125,"content_modified":149},"NCT06785636","A Phase 1b\u002F2a Study of Pocenbrodib as Monotherapy and in Combination With Darolutamide in Participants With mCRPC",[45],"2026-07-05T05:32:16.692755Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":155,"content_modified":156},"NCT06733350","Testosterone Replacement Therapy for the Treatment of Low Testosterone in Hypogonadal Men With Localized Prostate Cancer on Active Surveillance",[154],"Phase 4","2026-08-26T02:17:33.807405Z","2026-07-05T05:32:16.689941Z",{"nct_id":158,"title":159,"phases":160,"status":13,"updated_at":161,"content_modified":162},"NCT07548164","Comparing Two Different Boost Approaches in Radiation Therapy for People With Prostate Cancer",[38],"2026-08-26T02:16:23.080181Z","2026-07-05T05:32:16.684890Z",{"nct_id":164,"title":165,"phases":166,"status":13,"updated_at":167,"content_modified":168},"NCT07216248","Optimal PSA Triggered Individual Management of Androgen Sensitive Prostate Cancer",[12],"2026-08-26T02:17:09.131534Z","2026-07-05T05:32:16.664116Z",{"nct_id":170,"title":171,"phases":172,"status":13,"updated_at":173,"content_modified":174},"NCT07190300","TulmiSTAR-02: A Phase I\u002FII Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)",[45],"2026-08-26T02:16:44.178623Z","2026-07-05T05:32:16.658506Z",{"nct_id":176,"title":177,"phases":178,"status":13,"updated_at":179,"content_modified":180},"NCT07635238","A Study of Lower Dose Radiation Therapy for People With Prostate Cancer",[12],"2026-08-26T02:16:50.548894Z","2026-07-05T05:32:16.643284Z",{"nct_id":182,"title":183,"phases":184,"status":13,"updated_at":185,"content_modified":186},"NCT06800313","Study of HLD-0915 in Patients With Metastatic Prostate Cancer",[45],"2026-08-26T02:14:59.425132Z","2026-07-05T03:45:20.455373Z",{"nct_id":188,"title":189,"phases":190,"status":13,"updated_at":191,"content_modified":192},"NCT07543055","A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread",[118],"2026-08-26T02:16:06.684983Z","2026-07-05T03:45:20.252622Z",{"nct_id":194,"title":195,"phases":196,"status":13,"updated_at":197,"content_modified":198},"NCT07200830","Testing Different Dosing Schedules of the Anti-cancer Drug, Lutetium 177Lu PSMA RLT and Its Effect on Patients With Advanced Prostate Cancer, RECIPROCAL Trial",[38],"2026-08-26T02:17:11.311767Z","2026-06-17T02:29:30.057070Z",{"nct_id":200,"title":201,"phases":202,"status":13,"updated_at":203,"content_modified":204},"NCT06842498","A Study of FG-3246 in Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC)",[12],"2026-08-26T02:16:45.157238Z","2026-06-16T05:54:07.925062Z",{"nct_id":206,"title":207,"phases":208,"status":13,"updated_at":32,"content_modified":209},"NCT07611110","AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)",[38],"2026-05-29T15:36:40.229477Z",{"nct_id":211,"title":212,"phases":213,"status":13,"updated_at":214,"content_modified":215},"NCT07594002","Comparing Acupuncture vs. Sham Acupuncture for the Management of Hot Flashes in Prostate Cancer Patients Receiving Hormone Therapy",[],"2026-08-26T02:18:01.700186Z","2026-05-29T15:36:40.203322Z",{"nct_id":217,"title":218,"phases":219,"status":13,"updated_at":220,"content_modified":221},"NCT07590934","Phase Ib\u002FII Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer",[45],"2026-08-26T02:15:56.561131Z","2026-05-29T15:36:40.200576Z",{"nct_id":223,"title":224,"phases":225,"status":13,"updated_at":226,"content_modified":227},"NCT07493512","Trial of Xaluritamig in Adults With Metastatic Castration-resistant Prostate Cancer",[118],"2026-08-26T02:18:46.948970Z","2026-05-29T15:36:40.189706Z",{"nct_id":229,"title":230,"phases":231,"status":13,"updated_at":232,"content_modified":233},"NCT07581184","A Study of [225Ac]Ac-AKY-2519 in Patients With Metastatic Castration-Resistant Prostate Cancer",[118],"2026-08-26T02:18:31.164304Z","2026-05-13T02:55:06.784062Z",{"nct_id":235,"title":236,"phases":237,"status":13,"updated_at":238,"content_modified":239},"NCT07570979","A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer",[118],"2026-08-26T02:17:15.156099Z","2026-05-13T02:55:06.735178Z",{"nct_id":241,"title":242,"phases":243,"status":13,"updated_at":244,"content_modified":245},"NCT07365995","A Phase III Trial of BNT324 Versus Docetaxel in Metastatic Castration-resistant Prostate Cancer",[38],"2026-08-26T02:19:17.380174Z","2026-05-13T02:55:06.697069Z",{"nct_id":247,"title":248,"phases":249,"status":13,"updated_at":250,"content_modified":251},"NCT04221542","Study of AMG 509 in Participants With Metastatic Castration-Resistant Prostate Cancer",[118],"2026-08-26T02:17:38.215063Z","2026-05-05T02:43:29.729320Z",{"nct_id":253,"title":254,"phases":255,"status":13,"updated_at":256,"content_modified":257},"NCT06288113","Re-treatment With 177Lu-PSMA-617 for the Treatment of Metastatic Castration-Resistant Prostate Cancer, RE-LuPSMA Trial",[12],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:29.726777Z",{"nct_id":259,"title":260,"phases":261,"status":13,"updated_at":262,"content_modified":263},"NCT05915442","Adenosine Signaling Modulation and Immune Checkpoint Inhibition With Hormone Sensitive Oligometastatic Prostate Cancer",[12],"2026-08-26T02:16:46.951087Z","2026-05-05T02:43:29.710200Z",{"nct_id":265,"title":266,"phases":267,"status":13,"updated_at":268,"content_modified":269},"NCT06844383","A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate",[12],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:29.708217Z",{"nct_id":271,"title":272,"phases":273,"status":13,"updated_at":274,"content_modified":275},"NCT07287150","A Study to Test Inavolisib Treatment in Participants With Metastatic Castration-Resistant Prostate Cancer",[12],"2026-08-26T02:18:30.351130Z","2026-05-05T02:43:29.700513Z",{"nct_id":277,"title":278,"phases":279,"status":13,"updated_at":280,"content_modified":281},"NCT06172283","Intermittent Fasting in Prostate Cancer Patients Receiving Androgen Deprivation Therapy",[],"2026-08-26T02:18:19.586423Z","2026-05-05T02:43:29.696902Z",{"nct_id":283,"title":284,"phases":285,"status":13,"updated_at":287,"content_modified":288},"NCT05045066","Immunological Effects of Vitamin D Replacement Among Black\u002FAfrican American Prostate Cancer Patients",[286],"Early Phase 1","2026-08-26T02:16:12.203827Z","2026-05-05T02:43:29.691669Z",{"nct_id":290,"title":291,"phases":292,"status":13,"updated_at":293,"content_modified":294},"NCT06531499","A Study of Radiation Dosimetry, Safety, and Tolerability of Extended Lutetium (177Lu) Vipivotide Tetraxetan Treatment in Chemo-naïve Adults With Metastatic Castration-resistant Prostate Cancer: RADIOpharmaceutical DOSimetry Evaluation (RADIODOSE) Study",[118],"2026-08-26T02:18:11.042248Z","2026-05-05T02:43:29.662642Z",{"nct_id":296,"title":297,"phases":298,"status":13,"updated_at":299,"content_modified":300},"NCT07206056","An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)",[45],"2026-08-26T02:16:18.872924Z","2026-05-05T02:43:29.650271Z",{"nct_id":302,"title":303,"phases":304,"status":13,"updated_at":305,"content_modified":306},"NCT05800665","A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer",[118],"2026-08-26T02:17:45.190188Z","2026-05-05T02:43:29.650141Z",{"nct_id":308,"title":309,"phases":310,"status":13,"updated_at":311,"content_modified":312},"NCT07364071","Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer",[12],"2026-08-26T02:18:18.766496Z","2026-05-05T02:43:29.645312Z",[314,318,322,326,330,334,338,341,344,347,351,355,359,362,366,369,372,375,378,381,385,388,391,395],{"biomarker":315,"count":316,"slug":317},"FOLH1 Gene",34,"folh1-gene",{"biomarker":319,"count":320,"slug":321},"KLK3 Gene",31,"klk3-gene",{"biomarker":323,"count":324,"slug":325},"BRCA1 Gene",21,"brca1-gene",{"biomarker":327,"count":328,"slug":329},"BRCA2 Gene",18,"brca2-gene",{"biomarker":331,"count":332,"slug":333},"Partner and Localizer of BRCA2",13,"partner-and-localizer-of-brca2",{"biomarker":335,"count":336,"slug":337},"MSI1 Gene",10,"msi1-gene",{"biomarker":339,"count":336,"slug":340},"RAD51C Gene","rad51c-gene",{"biomarker":342,"count":336,"slug":343},"Serine\u002FThreonine-Protein Kinase Chk2","serine-threonine-protein-kinase-chk2",{"biomarker":345,"count":336,"slug":346},"TP53 Gene","tp53-gene",{"biomarker":348,"count":349,"slug":350},"RAD51D Gene",9,"rad51d-gene",{"biomarker":352,"count":353,"slug":354},"BRIP1 Gene",8,"brip1-gene",{"biomarker":356,"count":357,"slug":358},"Fanconi Anemia Group A Protein",7,"fanconi-anemia-group-a-protein",{"biomarker":360,"count":357,"slug":361},"Testosterone","testosterone",{"biomarker":363,"count":364,"slug":365},"CDK12 Gene",6,"cdk12-gene",{"biomarker":367,"count":364,"slug":368},"DNA Mismatch Repair Protein Mlh1","dna-mismatch-repair-protein-mlh1",{"biomarker":370,"count":364,"slug":371},"MRC1 wt Allele","mrc1-wt-allele",{"biomarker":373,"count":364,"slug":374},"Nibrin","nibrin",{"biomarker":376,"count":364,"slug":377},"PTEN Gene","pten-gene",{"biomarker":379,"count":364,"slug":380},"RAD51B Gene","rad51b-gene",{"biomarker":382,"count":383,"slug":384},"AHRR Gene",5,"ahrr-gene",{"biomarker":386,"count":383,"slug":387},"ATR Gene","atr-gene",{"biomarker":389,"count":383,"slug":390},"Decipher","decipher",{"biomarker":392,"count":393,"slug":394},"BARD1 Gene",4,"bard1-gene",{"biomarker":396,"count":393,"slug":397},"DNA Repair and Recombination Protein RAD54-Like","dna-repair-and-recombination-protein-rad54-like",[399,403,407,411,415,419,423,427,431,434,437,441,445,449,453,456,460,464,468,472,475,478,482,485],{"state":400,"count":401,"slug":402},"California",237,"california",{"state":404,"count":405,"slug":406},"New York",199,"new-york",{"state":408,"count":409,"slug":410},"Texas",195,"texas",{"state":412,"count":413,"slug":414},"Florida",157,"florida",{"state":416,"count":417,"slug":418},"Maryland",104,"maryland",{"state":420,"count":421,"slug":422},"Massachusetts",103,"massachusetts",{"state":424,"count":425,"slug":426},"Pennsylvania",102,"pennsylvania",{"state":428,"count":429,"slug":430},"Illinois",98,"illinois",{"state":432,"count":429,"slug":433},"Michigan","michigan",{"state":435,"count":429,"slug":436},"Ohio","ohio",{"state":438,"count":439,"slug":440},"Virginia",89,"virginia",{"state":442,"count":443,"slug":444},"Washington",82,"washington",{"state":446,"count":447,"slug":448},"Tennessee",81,"tennessee",{"state":450,"count":451,"slug":452},"Minnesota",78,"minnesota",{"state":454,"count":451,"slug":455},"New Jersey","new-jersey",{"state":457,"count":458,"slug":459},"Missouri",75,"missouri",{"state":461,"count":462,"slug":463},"South Carolina",72,"south-carolina",{"state":465,"count":466,"slug":467},"North Carolina",69,"north-carolina",{"state":469,"count":470,"slug":471},"Arizona",67,"arizona",{"state":473,"count":470,"slug":474},"Colorado","colorado",{"state":476,"count":470,"slug":477},"Wisconsin","wisconsin",{"state":479,"count":480,"slug":481},"Georgia",55,"georgia",{"state":483,"count":480,"slug":484},"Oregon","oregon",{"state":486,"count":487,"slug":488},"Nebraska",54,"nebraska"]